Research has consistently shown that treatments for depression are effective, with one meta-analysis demonstrating an average response rate of 54% across empirically supported treatments such as cognitive-behavioral therapy (CBT), interpersonal psychotherapy (IPT) and pharmacotherapy [1] . In the United States, depression has a lifetime prevalence rate of 13% [2] , with approximately 15% of depressed individuals suffering from unremitting or recurrent depression -even after multiple treatment approaches [3] . Thus, although treatments for depression are generally effective, there is ample room to improve both the initial efficacy and long-term maintenance of treatment gains. The personalization of treatment design and implementation represents an exciting and burgeoning area for improving outcomes in depression.
Currently, 'Strategy 3.2 0 of the National Institute of Mental Health's (NIMH) Strategic Plan [4] , calls for mental health researchers to 'expand and deepen the focus to personalize intervention research.' As well, investigators have called for an increased emphasis on idiographic research [5, 6] and the director of NIMH has called for research that can 'transform diagnostics and therapeutics' [7] . In medicine, the tailoring of interventions to individual needs is referred to as 'personalized medicine' and it has received a great deal of recent attention from the National Institutes of Health and the Food and Drug Administration [8] . Personalized medicine assumes that variability in treatment outcomes results from idiosyncratic initial conditions (e.g. genetic profiles) among individual patients [8] . The expectation is that identifying patterns of variation at the individual level will yield actionable, prescriptive information about which interventions are best-suited to which patients. Nevertheless, much work remains to be done. A recent systematic review and meta-analysis of clinical trials concluded that the present literature is insufficient to draw meaningful conclusions about personalized treatment for depression [9] .
The present review addresses the current (and recently expanding) literature on personalized assessment and treatment of depression, with the ultimate goal of encouraging further research in this domain.
Biological factors: genetics, biomarkers, and medications
Personalized medicine -the use of molecular genetic analysis for selecting and implementing targeted treatments -is a fast-growing area of research for optimizing depression treatment. A burgeoning body of recent literature has explored the role of genetics in the symptom trajectories and treatment outcomes of major depressive disorder (MDD). With recent advances in technology that enhance accessibility to genetic sequencing and analysis, studies have taken off in multiple directions to investigate implications of genetics and other biomarkers in relation to personalized assessment and treatment of depression. Although a recent genome-wide association (GWA) study of 2431 MDD patients and 3673 controls failed to identify a single genetic mechanism or pattern that predicts MDD diagnosis [10] , research has begun to examine the relationships between genes and treatment efficacy, indicating possibilities for personalized care. Table 1 provides a summary of recently identified candidate genes and their proposed functional roles. Adkins et al. [12] examined five monoamine candidate genes and found that carriers of the dopamine D4 5-repeat allele exhibited increasing depression during the transition to adulthood, whereas male carriers of the MAOA3.5 repeat allele exhibited a similar rise in late adolescence. In a study of 243 Han Chinese men and women with MDD, Yeh et al. [13] found that variations in the norepinephrine transporter gene SL6A2 were associated with remission of depression after venlafaxine treatment. In a review of pharmacogenetic and molecular genetic studies, Domschke found that the heritability of psychotic depressive phenotypes was 39%, and that psychotic depression shared several potential chromosomal loci with schizophrenia, schizoaffective disorder, and bipolar disorder [14] . In addition, Domschke found that variants of several genes possibly conferred an increased risk for psychotic symptoms, including BDNF, DBH, DTNBP1, DRD2, DRD4, GSK-3beta, and MAO-A. Thus, future pharmacogenetic work may facilitate the development of individually tailored treatments for psychotic phenotypes based on individual genotypes.
Mamdani et al. [15] examined genetic predictors of citalopram response. They identified SMAD7 and SIGLECP3 as two candidate genes. These genes were the most differentially expressed and significantly downregulated in responders to treatment. Menke [16] found that the most promising candidate genes for depression treatment response are those related to the hypothalamic-pituitary-adrenal (HPA) axis, inflammation, and neuroplasticity; however, another study looking to identify single nucleotide polymorphisms (SNPs) predictive of antidepressant response found that looking at SNPs related to the HPA axis, endocannabinoid, and immune systems together predicted antidepressant response better than looking at these polymorphisms in isolation [17 ] . In a GWA study in a sample of over 10,000 individuals, Wray et al. [10] failed to detect main effects for any SNP on depression. These authors estimated that samples 1.8-2.4 times greater are required to sufficiently power genetic association studies of MDD. In addition, Preskorn et al. [18 ] warn that personalized medicine based solely on genetics may be misleading, given differences between 'predictor genes' and 'target genes' for antidepressive medications. That is, the biomolecules affected by pharmacological treatment (thereby improving symptoms) can be unrelated to the genes that predict individual response to treatment [19 ] . ) study examined the relationship between ancestral background and outcome after depression treatment in a large cohort of 1892 individuals. Robust correlations between ancestry and both drug efficacy and side effects were observed in 89 different treatment-outcome combinations. These data support the notion that heritable factors (indexed by ancestry) influence side effects as well as outcome of depression treatment.
Other biological approaches
Transcranial magnetic stimulation (TMS), the stimulation of regions of the brain via an electromagnetic coil, is an FDA-approved intervention for MDD. Arns et al. were able to reliably identify non-responders to TMS treatment with low false-positive rates [25] . Non-responders tended to exhibit, first, increased fronto-central theta electroencephalography (EEG) power; second, a slower anterior individual alpha peak frequency; third, a larger P300 amplitude; and fourth decreased pre-frontal delta and beta concor-
Psychosocial factors and patient characteristics
In addition to promising biological and genetic approaches, researchers have explored patient characteristics and patient-related psychosocial factors that are predictive of treatment outcome. Hill et al. ] have developed the probability of treatment benefit chart, a probabilistic, individualized metric for determining the chances a given treatment will benefit an individual with various baseline characteristics.
Huang et al.
[31] analyzed the electronic health records of 40,651 patients via Least Absolute Shrinkage and Selection Operator logistic regression models. These authors found that they were able to predict future diagnosis of depression as much as a year in advance, with an area under the receiver operating characteristic curve (AUC) of 0.70-0.80. In addition, they were able to differentiate minimal/mild depression from severe depression with an AUC of 0.72. In turn, baseline depression severity was the strongest predictor of treatment response for both pharmacotherapy and psychotherapy -with higher levels of depression predicting poorer outcome in both cases.
DeRubeis et al. [32
] recently introduced the Personalized Advantage Index (PAI) to facilitate optimal selection of treatment plans by five variables (marital status, employment, life events, personality disorder, prior medication trials). Participants were assigned to their 'optimal' or 'non-optimal' treatment based on PAI scores; those assigned to 'optimal' treatment had significantly better treatment outcomes suggesting that this index is useful in guiding treatment selection. Although applied specifically to a pharmacologic versus psychotherapeutic choice, this method can be applied to any two therapies with existing archival data.
Model-based and statistical methods
Traditionally, researchers have examined 'what works for whom ' [33] via moderator analyses. However, these efforts have been largely unsuccessful, suffering from poor replication and statistical bias due a lack of random assignment. Wallace et al.
[34] recently proposed a novel approach for detecting and interpreting moderator effects via the combination of multiple individual moderators. In a sample of 291 depressed adults, they demonstrated that the combined moderator provided a disordinal (i.e. crossover) effect whereby the preferential benefit of medication was found below the cross point and psychotherapy above the cross point.
Other recent statistical innovations include latent class analysis (LCA) and growth mixture modeling (GMM), which are able to isolate clusters (classes) of responders in psychotherapy outcome data [35] [36] [37] , with the assumption that understanding the predictors of class membership can generate insight into optimal interventions. In one study, GMM was used to demonstrate that CBT was superior to medication in severely depressed young women at one-year follow-up, with no difference between the interventions at one year in those with moderate depression [38 ] . Another study found no relationship between intervention modality and treatment response, but demonstrated that non-responder class membership was predicted by coping strategies, emotional lability, and introversion [39] .
Two studies have recently examined the latent class structures of interpersonal profiles in MDD. Grosse Holtforth et al. [40] used LCA to examine the distribution of interpersonal circumplex structures in 361 depressed patients and 959 patients with other primary diagnoses. These authors found eight distinct interpersonal classes, with a significantly greater distribution of submissive personality types within the depressed patients. Moreover, class membership was significantly related to baseline severity, with highly introverted individuals exhibiting the most severe depression. Cain et al. [41] conducted an LCA of 312 depressed patients and returned six interpersonal classes -extraverted, dominant, arrogant, cold, submissive, and unassuming. Submissive personality predicted greater chronicity and poorer functioning, indicating a possible need for more intensive or specialized care in these individuals.
Patient preference
Perhaps the most obvious and direct way to personalize treatment is to confer directly with depressed individuals in order to tailor interventions to their preferences. Wittink et al. [42] recently provided a method for determining 'values markers,' profiles of patient values and perceptions of what needs to change in depression treatment.
LCA of these makers yielded three preference profiles: a pro-counseling/anti-medication profile, a medical setting preference with an aversion to powerful medications, and a preference for medication over counseling. Most participants were classified in 'profile 1 0 in the context of severe depression, and participants generally preferred mental health treatment settings over primary care or spiritual settings. Gaudiano et al. [43] found that men and women may have different beliefs about the cause of their depression, and differing views on the acceptability of treatment regimens. These authors examined the perceived causes of depression and acceptability of medication in 52 psychiatric inpatients and found that women were more likely to make biological causal attributions, and that men who made such attributions were less willing to undergo pharmacologic treatment.
Future directions
Bellon and colleagues have developed the predictD algorithm for determining the presence, level, and risk of onset of MDD for primary care intervention [44 ] . These investigators are currently conducting a randomized controlled trial of predictD versus usual care, with preliminary results suggesting that patients are comfortable learning about their personal risk of depression [45] . Saveanu and colleagues recently reported initial outcomes from the International Study to Predict Optimized Treatment in Depression (iSPOT-D), an RCT examining escitalopram, sertraline, and venlafaxine-extended release in 1008 treatment-seeking outpatients [46 ] . Having demonstrated equivalent results across the three treatments, these authors intend to identify potential neurobiological and genetic predictors of optimal treatment. Finally, our group is currently conducting a proof-of-concept trial based on recent work by the first author [47] . Individuals with MDD and/or generalized anxiety disorder complete brief, phone-based surveys related to the clinical criteria for both disorders, four times per day for 30 days. These data are analyzed to distil the core, latent factors for each individual and the dynamic, predictive relationships among symptoms moment-to-moment. The results of these analyses are then used to make prescriptive decisions about the construction and implementation of modular therapies on a person-by-person basis. Zajkowska ZE, Englund A, Zunszain PA: Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. Pharmacogenomics 2014, 15:687-698. This study found that examining SNPs related to the HPA axis, endocannabinoid, and immune systems in combination predicted antidepressant response better than looking at these polymorphisms by themselves. This could provide more insight into the types of genes we can use to predict antidepressant response. In addition, depression treatment response may be influenced by multiple genes or systems of genes in concert with one another.
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